Cel Sci (CVM) Change in Receivables (2010 - 2022)
Cel Sci (CVM) posted Change in Receivables of -$109844.0 for Q3 2022, up 79.37% sequentially from -$532328.0 in Q1 2021.
Cel Sci (CVM) Change in Receivables (2010 - 2022) Analysis & Trends
Cel Sci has reported Change in Receivables for 12 years, with the latest figure at -$109844.0 in Q3 2022.
- Quarterly Change in Receivables changed N/A year-over-year to -$109844.0 in Q3 2022, while the trailing twelve-month figure through Sep 2022 was -$109844.0 (changed N/A YoY) and the FY2022 annual result came in at -$54922.0, changed N/A from the prior year.
- Change in Receivables rose to -$109844.0 in Q3 2022 per CVM's latest filing, from -$532328.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $532328.0 in Q4 2020 and troughed at -$532328.0 in Q1 2021.
- A 5-year average of $17827.6 and a median of $2959.5 in 2018 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2018 and 2020: Change in Receivables surged 91975.0% in 2018, then slumped 4503.87% in 2020.
- Over 5 years, Change in Receivables stood at $10105.0 in 2018, then tumbled by 379.84% to -$28278.0 in 2019, then jumped by 1982.48% to $532328.0 in 2020, then slumped by 200.0% to -$532328.0 in 2021, then soared by 79.37% to -$109844.0 in 2022.
- According to Business Quant data, Change in Receivables over the past three periods registered -$109844.0, -$532328.0, and $532328.0 for Q3 2022, Q1 2021, and Q4 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -109,844.00 |
| Sep 30, 2022 | -109,844.00 |
| Mar 31, 2021 | -532,328.00 |
| Mar 31, 2021 | -532,328.00 |
| Dec 31, 2020 | 532,328.00 |
| Dec 31, 2020 | 532,328.00 |
| Sep 30, 2020 | 200,085.00 |
| Sep 30, 2020 | 200,085.00 |
| Jun 30, 2020 | -192,718.00 |
| Jun 30, 2020 | -192,718.00 |
| Mar 31, 2020 | 28,754.00 |
| Mar 31, 2020 | 28,754.00 |
| Dec 31, 2019 | -28,278.00 |
| Dec 31, 2019 | -28,278.00 |
| Sep 30, 2019 | 55,499.00 |
| Sep 30, 2019 | 55,499.00 |
| Jun 30, 2019 | -4,186.00 |
| Jun 30, 2019 | -4,186.00 |
| Mar 31, 2019 | -5,526.00 |
| Mar 31, 2019 | -5,526.00 |